LungMATCH Partnership Expands Access to Tumor Testing
Tuesday, November 15, 2016
- Today, Lung Cancer Alliance (LCA) and Perthera, Inc., a precision medicine company, are excited to announce a unique collaborative program to bring best-in-class molecular tumor testing to lung cancer patients. The second phase of LCA’s LungMATCH program
, this effort seeks to increase access to comprehensive molecular testing that can identify the best path to treatment for those diagnosed with the number one cancer killer.
“Through this partnership, patients will have greater access to testing that is crucial in the search for the most appropriate treatment option,” said Jennifer C. King, PhD, Director of Science and Research, Lung Cancer Alliance. “As new medications become available, it is becoming increasingly more important for patients to have the most detailed information about their cancer. This program will help patients to make more informed, individualized treatment decisions.”
Perthera’s service combines full molecular diagnostic testing with precision data to connect those newly diagnosed with lung cancer or those whose tumors have grown or progressed to their best clinical trial options. Perthera’s Precision Cancer Analysis (PCA) allows for a detailed interpretation of a patient’s tumor based on which detailed recommendations can be presented to patients and their cancer care teams to enhance treatment decisions.
“This is not only an important project for those with lung cancer, but it is a benchmark in the evolution of precision medicine,” Perthera CEO Andrew Mignatti said. “With LungMATCH, Lung Cancer Alliance is taking a major step in the evolution of medicine, adding advanced biological testing and data analysis to the tools oncologists and the entire cancer care team use in their treatment strategy.”
To find the best pathways to treatments through this service visit: www.lungmatch.org
or call 1-800-298-2436.